December 1, 2021 | Targeted Therapies in Oncology

Advancing T-Cell Redirecting Agents in Prostate Cancer

December 17, 2021

Clinical Articles

During a conference presentation, A. Oliver Sartor, MD, explained how researchers are building upon the principles of T-cell redirecting agents, such as bispecific T-cell engagers, from other cancer types for the sake of treating patients with prostate cancer.

Repotrectinib Shows Efficacy in Expanded Cohorts of NTRK+ Solid Tumors

December 14, 2021

Clinical Articles

Updated findings from the phase 1/2 TRIDENT-1 trial evaluating repotrectinib showed efficacy in patients with neurotrophic tyrosine receptor kinase fusion-positive advanced solid tumors in expanded cohorts.